NCT06634875View on ClinicalTrials.gov

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

isunakinra

Isunakinra is a potent IL1R1 inhibitor

Trial Locations (2)

90089

RECRUITING

USC/Norris Cancer Center, Los Angeles

92658

RECRUITING

Hoag Memorial Hospital Presbyterian, Newport Beach

Sponsors
All Listed Sponsors
lead

Buzzard Pharmaceuticals

INDUSTRY

NCT06634875 - Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) | Biotech Hunter | Biotech Hunter